Alex_Zisson

H.I.G.

Alex joined H.I.G. Capital as a Managing Director in January 2016. He joined Arvelle’s Board of Directors in 2019 at the company’s inception. At H.I.G., Alex focuses on investments in the biopharmaceuticals industry, especially in pharmaceuticals, generics, drug delivery and specialty pharma and biotechnology. Along with Arvelle, he currently serves on the board of directors for Clarus Therapeutics, Leiters, Neurana Pharma, Taconic Biosciences and BioVectra. Prior to H.I.G., Alex was spent 13 years making similar investments at Thomas, McNerney & Partners. Previous board seats included Auspex Pharmaceuticals (sold to Teva), InnoPharma (sold to Pfizer), Quinnova (sold to Amneal), Celator (public), Zogenix (public), Tranzyme (merged with Ocera) and observer roles at PCI Pharma Services (sold to Partners Group) and Coley Pharmaceutical (sold to Pfizer). Alex is the co-chair of the Business Advisory Council of the Children’s Tumor Foundation, on the advisory board for Brown University’s medical school, and is on the Life Sciences Council for Springboard Enterprises, a group that assists women entrepreneurs. He is also a board member for the Greenwich Council of the Boy Scouts of America. He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.